Development of oxybutynin chloride topical gel for overactive bladder

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation subcommittee of the International Continence Society. Urology. 2003;61(1):37–49.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336.
   PubMed Web of Science ®Google Scholar
• Milsom I, Irwin DE. A cross-sectional, population-based, multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: Results from the EPIC study. Eur Urol. 2007;6:4–9.
   Web of Science ®Google Scholar
• Gillespie JI, van Koeveringe GA, de Wachter SG, de Vente J. On the origins of the sensory output from the bladder: The concept of afferent noise. BJU Int. 2009;103(10):1324–1333.
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.
   PubMed Web of Science ®Google Scholar
• Thomas L, Culley EJ. Overactive bladder disease: The urge for better therapies. J Manag Care Pharm. 2008;14(4):381–386.
   PubMed Web of Science ®Google Scholar
• Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000;55(5A Suppl):33–46.
   PubMed Web of Science ®Google Scholar
• Masuda H, Kim YT, Tyagi S, Chancellor MB, de Miguel F, Yoshimura N. Local effects of antimuscarinics. Urol Clin North Am. 2006;33(4):511–518, ix-x.
   PubMed Web of Science ®Google Scholar
• Hedlund P, Streng T, Lee T, Andersson KE. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J Urol. 2007;178(1):326–331.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–562.
   PubMed Web of Science ®Google Scholar
• Staskin DR, Macdiarmid SA. Using anticholinergics to treat overactive bladder: The issue of treatment tolerability. Am J Med. 2006;119(3 Suppl 1):9–15.
   PubMedGoogle Scholar
• Basra RK, Wagg A, Chapple C, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774–779.
   PubMed Web of Science ®Google Scholar
• D’Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14(3):291–301.
   PubMed Web of Science ®Google Scholar
• Appell RA. Pharmacotherapy for overactive bladder: An evidence-based approach to selecting an antimuscarinic agent. Drugs. 2006;66(10):1361–1370.
   PubMed Web of Science ®Google Scholar
• GELNIQUE (oxybutynin chloride) 10% gel [Prescribing information]. Corona, CA: Watson Pharmaceuticals Inc; 2009.
   Google Scholar
• Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: A randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009;181(4):1764–1772.
   PubMed Web of Science ®Google Scholar
• Oxytrol® oxybutynin transdermal system [Prescribing information]. Corona, CA: Watson Pharmaceuticals Inc; 2006.
   Google Scholar
• Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166(1):140–145.
   PubMed Web of Science ®Google Scholar
• Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78(6):696–702.
   PubMed Web of Science ®Google Scholar
• Roberts MS, Cross SE, Anissimov YG. Factors affecting the formation of a skin reservoir for topically applied solutes. Skin Pharmacol Physiol. 2004;17(1):3–16.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Newman DK, Sand PK, et al. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, showering, sunscreen, and person-to-person transference. Clin Drug Investig. 2011; In press.
   Web of Science ®Google Scholar
• Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168(2):580–586.
   PubMed Web of Science ®Google Scholar
• Caramelli KE, Staskin DR, Volinn W. Steady-state pharmacokinetics of an investigational oxybutynin topical gel in comparison with oxybutynin transdermal system. J Urol. 2008;179(4):513–514.
   Web of Science ®Google Scholar
• Caramelli KE, Thomas H, Stanworth S, Hoel G. Steady-state bioavailability of oxybutynin topical gel at 3 different application sites. Poster presented at the Annual Senior Care Pharmacy Meeting of the American Society of Consultant Pharmacists, November 19–22, 2008, New Orleans, LA.
   Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62(2):237–242.
   PubMed Web of Science ®Google Scholar
• Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: A multicentre, community-based, randomized study. BJUInt. 2007;99(4):836–844.
   PubMed Web of Science ®Google Scholar
• Berger RS, Bowman JP. A reappraisal of the 21-day cumulative irritation test in man. J Toxicol Cutaneous Ocul Toxicol. 1982;1(2):109–115.
   Google Scholar
• Newman DK, Hanno PM, Dmochowski RR, et al. Effects of oxybutynin chloride topical gel on health-related quality of life in adults with overactive bladder: A randomized, double-blind, placebo-controlled study. Clinical Medicine Insights: Therapeutics. 2010;2:889–896.
   Google Scholar
• Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother. 2009;10:3103–3111.
   PubMed Web of Science ®Google Scholar